Publication date: 05-04-2012 10:58
MuIti-component therapeutic strategies are frequently indicated for the treatment of heterogeneous diseases as cancer. However, the antitumor activity of drug combinations is extremely dependent of the molecular ratio of the combined drugs. This patent describes a multi -targeting system comprising a nanocarrier that was engineered in order to exhibit small size, high stability over time, high encapsulation yields of nucleic acids and the ability to specifically bind to receptors overexpressed at the surface of cancer cells. Further developments were performed in order to simultaneously encapsulate nucleic acids (gene silencing agents) and antitumural drugs (imatinib) in molar ratios allowing both molecules to be used in therapeutic doses. Therefore, with this product it is possible to mediate specific delivery to cancer cells and to address two specific molecular targets (a transcript and a protein) This unique properties thus render the system a great potential for cancer treatment, namely when resistance to chemotherapy is associated.
|Data de prioridade||03-03-2010|
|Documento de patente|||
|Licenciamento||Treat U, Lda|